Molecular farming (biopharming) uses plants or plant cell cultures as bioreactors to produce vaccines, antibodies, and enzymes. Fast-growing species like Nicotiana benthamiana are transiently expressed with agroinfiltration or viral vectors, yielding high-value proteins within weeks rather than months required for stainless-steel bioreactors. Downstream processing recovers GMP-grade products at lower capital intensity, leveraging existing agricultural acreage.
Pharma companies, governments, and startups deploy biopharming for pandemic preparedness, orphan drugs, and enzymes for industrial processes where flexibility and rapid scale-up matter. Firms such as Kentucky BioProcessing and Medicago have demonstrated field-to-vial timelines measured in weeks, while plant-made dairy proteins and cosmetic actives expand non-pharma use cases.
Future systems will integrate controlled-environment greenhouses, automated infiltration robots, and digital batch records connected to regulatory portals. Key hurdles involve consistent glycosylation profiles, containment protocols to prevent gene flow, and regulatory harmonization between agriculture and pharma authorities. Contract manufacturing networks and insurance structures for crop-as-factory models will drive broader adoption.
